The Lupus Nephritis Treatment Market is characterized by a diverse range of therapeutic approaches designed to address the complex needs of lupus nephritis patients. The market was valued at USD 3 billion in 2025 and is forecast to reach USD 6.5 billion by 2035 at a CAGR of 5.4%.

By treatment type, the market includes immunosuppressants, corticosteroids, antimalarials, biologics, and monoclonal antibodies. Immunosuppressants represent a leading segment, while biologics are expected to experience strong growth because of advances in targeted treatment and personalized medicine.

The market is also segmented by route of administration into oral, intravenous, subcutaneous, and intramuscular categories. By patient type, it includes adults, pediatrics, and geriatrics. Diagnosis categories comprise primary lupus nephritis and secondary lupus nephritis.

The competitive landscape includes major pharmaceutical companies such as Novartis, Pfizer, Eli Lilly, Bristol Myers Squibb, Roche, Gilead Sciences, Teva Pharmaceutical, GlaxoSmithKline, Merck & Co., UCB, Amgen, Johnson & Johnson, AbbVie, Sanofi, and AstraZeneca.

Companies are focusing on research and development, innovative drug candidates, strategic collaborations, and targeted therapies to strengthen their positions. Growing competition from biotechnology companies is also encouraging innovation within the market.

Regionally, North America remains a major market, while Europe and Asia-Pacific continue to provide opportunities for expansion. Increasing disease awareness, improved diagnosis, and advances in treatment technologies are expected to influence the competitive landscape throughout the forecast period.